Peripheral Blood Absolute Lymphocyte Count At Diagnosis Can Be Used To Risk-Stratify Patients With Multiple Myeloma, Study Indicates

Healio (1/23, Shinkle) reports, “Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.” The research showed that “continued monitoring of absolute lymphocyte count...during treatment and follow-up can predict OS.” The findings were published in Blood Advances.